Pauline Dürr

Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie

From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy (2024) Cuba L, Dürr P, Dörje F, Fromm M, Schlichtig K Journal article Optimizing Medication Safety with Oral Antitumor Therapy: A Methodological Approach for the Real-World Implementation of the AMBORA Competence and Consultation Center (2023) Cuba L, Schlichtig K, Dürr P, Inwald EC, Fromm M, Dörje F Journal article Inconsistencies of absolute drug-drug contraindication reports: Analysis of Summaries of Product Characteristics of commonly prescribed drugs (2023) Weisbach L, Schuster AK, Hartmann M, Dürr P, Then M, Andrikyan W, Fromm M, et al. Journal article, Original article Characteristics and Cost of Unscheduled Hospitalizations in Patients Treated with New Oral Anticancer Drugs in Germany: Evidence from the Randomized AMBORA Trial (2022) Dürr P, Meier F, Schlichtig K, Schramm A, Schötz L, Fromm M, Dörje F Journal article POLAR-POLypharmacy, drug interActions and Risks-how can data from inpatient care support their assessment? (2022) Scherag A, Andrikyan W, Dreischulte T, Dürr P, Fromm M, Gewehr J, Jaehde U, et al. Journal article Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022) Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Conference contribution New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial (2022) Schlichtig K, Cuba L, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Journal article Clarity, clinical applicability and relevance of absolute contraindications in official 'Summaries of Product Characteristics' (SmPCs) (2022) Andrikyan W, Then M, Dürr P, Jung-Poppe L, Schuster A, Weisbach L, Farker K, et al. Conference contribution Development and validation of an LC-MS method for drug exposure measurement of 57 oral antitumor drugs in human plasma (2022) Kehl N, Dürr P, Schlichtig K, Maas R, Fromm M, Geßner A, Taudte V Conference contribution Identification of diagnosis-related contraindications based on the medication plan alone (2022) Andrikyan W, Then M, Gassmann KG, Tuemena T, Dürr P, Fromm M, Maas R Conference contribution